Literature DB >> 4069203

Specific release of proteoglycans from human natural killer cells during target lysis.

R E Schmidt, R P MacDermott, G Bartley, M Bertovich, D A Amato, K F Austen, S F Schlossman, R L Stevens, J Ritz.   

Abstract

Natural killer (NK) activity is mediated by a small population of peripheral blood cells that exhibit the homogeneous morphology of large granular lymphocytes (LGL). In recent studies, human NK cell clones have been shown to contain a 200,000-Mr (relative molecular mass) protease-resistant chondroitin sulphate A proteoglycan, which has been localized to the secretory granule by X-ray dispersive analysis and by its resistance to cleavage by extracellular addition of chondroitinase AC or ABC (ref. 7). In the present study, we have used six different human NK cell clones to demonstrate that release of 35S-proteoglycan correlates closely with cytolytic activity against various NK cell targets. When NK activity is blocked by monoclonal antibodies at either the effector cell level (LFA-1) or at the target cell level (TNKTAR), there is a concomitant decrease in exocytosis of proteoglycan. Monoclonal antibodies directed against recognition structures, for example anti-NKTa and anti-T3 (ref. 10), function as soluble stimuli, capable of initiating the release of 35S-proteoglycan. Taken together, these results provide strong evidence for the stimulus-specific release of chondroitin sulphate A proteoglycans from NK cells when the cytolytic process is activated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4069203     DOI: 10.1038/318289a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  26 in total

1.  Granzymes, cytotoxic granules and cell death: the early work of Dr. Jurg Tschopp.

Authors:  J A Trapani
Journal:  Cell Death Differ       Date:  2011-11-18       Impact factor: 15.828

2.  Two cytotoxic cell proteinase genes are differentially sensitive to sodium butyrate.

Authors:  C J Frégeau; C D Helgason; R C Bleackley
Journal:  Nucleic Acids Res       Date:  1992-06-25       Impact factor: 16.971

3.  Defect of a complement receptor 3 epitope in a patient with systemic lupus erythematosus.

Authors:  T Witte; F L Dumoulin; J E Gessner; J Schubert; O Götze; C Neumann; R F Todd; H Deicher; R E Schmidt
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

4.  Heterogeneity of human natural killer cells in the spleen.

Authors:  T Witte; K Wordelmann; R E Schmidt
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

5.  Enhancement of natural killer function through activation of the T11 E rosette receptor.

Authors:  R E Schmidt; J M Michon; J Woronicz; S F Schlossman; E L Reinherz; J Ritz
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

6.  Identification and sequencing of cDNA clones encoding the granule-associated serine proteases granzymes D, E, and F of cytolytic T lymphocytes.

Authors:  D Jenne; C Rey; J A Haefliger; B Y Qiao; P Groscurth; J Tschopp
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

7.  Induction of expression of cell-surface homologous restriction factor upon anti-CD3 stimulation of human peripheral lymphocytes.

Authors:  D E Martin; L S Zalman; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

8.  Ultrastructure of proteoglycans in the specific granules of guinea-pig basophilic leukocytes as demonstrated by cuprolinic blue staining.

Authors:  G Landemore; M Quillec; J Izard
Journal:  Histochem Cell Biol       Date:  1995-03       Impact factor: 4.304

Review 9.  Small proteoglycans.

Authors:  H Kresse; H Hausser; E Schönherr
Journal:  Experientia       Date:  1993-05-15

10.  Serglycin proteoglycan deletion induces defects in platelet aggregation and thrombus formation in mice.

Authors:  Donna S Woulfe; Joanne Klimas Lilliendahl; Shelley August; Lubica Rauova; M Anna Kowalska; Magnus Abrink; Gunnar Pejler; James G White; Barbara P Schick
Journal:  Blood       Date:  2007-12-19       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.